Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-04-2019 | Ovarian Cancer | Original Article – Cancer Research

Expression of Syk and MAP4 proteins in ovarian cancer

Authors: Siwei Zhang, Suha Deen, Sarah J. Storr, Anqi Yao, Stewart G. Martin

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2019

Abstract

Purpose

We have previously reported on the prognostic importance of the calpain family of proteins in ovarian cancer, especially calpain-2. Spleen tyrosine kinase (Syk) phosphorylates a variety of cytoskeletal proteins with studies suggesting potential interactions between Syk and conventional calpains. Microtubule-associated protein 4 (MAP4) has been reported to be regulated by Syk.

Methods

The current study assessed Syk and MAP4 protein expression, by immunohistochemistry on a tissue microarray comprised of cores from primary ovarian carcinomas (n = 575), to evaluate associations with patient clinical outcomes and other clinicopathological factors and sought to determine whether there were any correlations between the expression of Syk, MAP4 and the calpain system.

Results

MAP4 expression was significantly associated with ovarian cancer histological subtype (P < 0.001), stage (P = 0.001), grade (P < 0.001) and residual tumour (P = 0.005). Despite this finding, we found no significant association existing between MAP4 expression and overall survival. Syk expression was also found significantly associated with histological subtype (P < 0.001). Syk seems to play a contradictory role with respect to tumour progression: low cytoplasmic Syk expression was significantly associated with low stage (P = 0.013), and low nuclear Syk expression with chemo-resistance in patients treated with taxane-containing therapy (P = 0.006). Interestingly, despite the lack of association in the whole cohort, high nuclear Syk expression was significantly associated with better overall survival in certain subgroups (P = 0.001).

Conclusions

The current study indicates a lack of correlation between calpain-2 expression and Syk and MAP4. Syk, MAP4 and calpain-1 appeared to significantly correlate with each other in the whole cohort, with calpain-1 being more highly associated with MAP4 and Syk in mucinous carcinomas. Overall, the current results suggest that Syk, MAP4, and calpain-1 expression are correlated with each other and these proteins may be involved in early stages of tumour spread.

Available only for authorised users

Aoki D, Oda Y, Hattori S, Taguchi K, Ohishi Y, Basaki Y, Oie S, Suzuki N, Kono S, Tsuneyoshi M et al (2009) Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res 15(4):1473–1480. https://doi.org/10.1158/1078-0432.CCR-08-1274 CrossRefPubMed

Baldock D, Graham B, Akhlaq M, Graff P, Jones CE, Menear K (2000) Purification and characterization of human Syk produced using a baculovirus expression system. Protein Expr Purif 18(1):86–94CrossRefPubMed

Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21):7252–7259CrossRef

Chuanliang P, Yunpeng Z, Yingtao H, Qifeng S, Xiaogang Z, Bo C (2016) Syk expression in non-small-cell lung cancer and its relation with angiogenesis. J Cancer Res Ther 12(2):663–666. https://doi.org/10.4103/0973-1482.154082 CrossRefPubMed

Coopman PJ, Mueller SC (2006) The Syk tyrosine kinase: a new negative regulator in tumor growth and progression. Cancer Lett 241(2):159–173 (Epub 2006 Jan 27) CrossRefPubMed

Coopman PJ, Do MT, Barth M, Bowden ET, Hayes AJ, Basyuk E, Blancato JK, Vezza PR, McLeskey SW, Mangeat PH, Mueller SC (2000) The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 406(6797):742–747CrossRefPubMed

Cucchiarelli V, Hiser L, Smith H, Frankfurter A, Spano A, Correia JJ, Lobert S (2008) Beta-tubulin isotype classes II and V expression patterns in nonsmall cell lung carcinomas. Cell Motil Cytoskelet 65(8):675–685. https://doi.org/10.1002/cm.20297 CrossRef

Divaris K, Vann WF Jr, Baker AD, Lee JY (2012) Examining the accuracy of caregivers’ assessments of young children’s oral health status. J Am Dent Assoc 143(11):1237–1247CrossRefPubMedPubMedCentral

Fei B, Yu S, Geahlen RL (2013) Modulation by Syk of Bcl-2, calcium and the calpain-calpastatin proteolytic system in human breast cancer cells. Biochim Biophys Acta 1833(10):2153–2164. https://doi.org/10.1016/j.bbamcr.2013.05.010 CrossRefPubMedPubMedCentral

Geahlen RL (2014) Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol Sci 35(8):414–422. https://doi.org/10.1016/j.tips.2014.05.007 CrossRefPubMedPubMedCentral

Ghotra VP, He S, van der Horst G, Nijhoff S, de Bont H, Lekkerkerker A, Janssen R, Jenster G, van Leenders GJ, Hoogland AM et al (2015) Syk is a candidate kinase target for the treatment of advanced prostate cancer. Cancer Res 75(1):230–240. https://doi.org/10.1158/0008-5472.CAN-14-0629 CrossRefPubMed

Gonscherowski V, Becker BF, Moroder L, Motrescu E, Gil-Parrado S, Gloe T, Keller M, Zahler S (2006) Calpains: a physiological regulator of the endothelial barrier? Am J Physiol Heart Circ Physiol 290(5):H2035–H2042CrossRefPubMed

Grädler U, Schwarz D, Dresing V, Musil D, Bomke J, Frech M, Greiner H, Jäkel S, Rysiok T, Müller-Pompalla D, Wegener A (2013) Structural and biophysical characterization of the Syk activation switch. J Mol Biol 425(2):309–333. https://doi.org/10.1016/j.jmb.2012.11.007 CrossRefPubMed

Hong J, Hu K, Yuan Y, Sang Y, Bu Q, Chen G, Yang L, Li B, Huang P, Chen D, Liang Y, Zhang R, Pan J, Zeng YX, Kang T (2012) CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J Clin Investig 122(6):2165–2175. https://doi.org/10.1172/JCI61380 CrossRefPubMed

Jiang YY, Shang L, Shi ZZ, Zhang TT, Ma S, Lu CC, Zhang Y, Hao JJ, Shi C, Shi F et al (2016) Microtubule-associated protein 4 is an important regulator of cell invasion/migration and a potential therapeutic target in esophageal squamous cell carcinoma. Oncogene 35(37):4846–4856. https://doi.org/10.1038/onc.2016.17 CrossRefPubMed

Jinawath N, Vasoontara C, Jinawath A, Fang X, Zhao K, Yap KL, Guo T, Lee CS, Wang W, Balgley BM et al (2010) Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS One 5(6):e11198. https://doi.org/10.1371/journal.pone.0011198 CrossRefPubMedPubMedCentral

Katz E, Lareef MH, Rassa JC, Grande SM, King LB, Russo J, Ross SR, Monroe JG (2005) MMTV Env encodes an ITAM responsible for transformation of mammary epithelial cells in three-dimensional culture. J Exp Med 201(3):431–439CrossRefPubMedPubMedCentral

Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Gervais-Bird J, Madden R, Paquet ER, Koh C, Venables JP, Prinos P et al (2008) Multiple alternative splicing markers for ovarian cancer. Cancer Res 68(3):657–663. https://doi.org/10.1158/0008-5472.CAN-07-2580 CrossRefPubMed

Krisenko MO, Geahlen RL (2015) Calling in Syk: Syk’s dual role as a tumor promoter and tumor suppressor in cancer. Biochim Biophys Acta 1853(1):254–263. https://doi.org/10.1016/j.bbamcr.2014.10.022 CrossRefPubMed

Krisenko MO, Cartagena A, Raman A, Geahlen RL (2014) Nanomechanical property maps of breast cancer cells as determined by multiharmonic atomic force microscopy reveal Syk-dependent changes in microtubule stability mediated by MAP1B. Biochemistry 54:60–68. https://doi.org/10.1021/bi500325n CrossRefPubMedPubMedCentral

Luangdilok S, Box C, Patterson L, Court W, Harrington K, Pitkin L, Rhŷs-Evans P, O-charoenrat P, Eccles S (2007) Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. Cancer Res 67(16):7907–7916CrossRefPubMed

McShane LM, Altman DG, Sauerbrei W. Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93:387–391CrossRefPubMedPubMedCentral

Mohammad DK, Nore BF, Gustafsson MO, Mohamed AJ, Smith CIE (2016) Protein kinase B (AKT) regulates SYK activity and shuttling through 14-3-3 and importin 7. Int J Biochem Cell Biol 78:63–74. https://doi.org/10.1016/j.biocel.2016.06.024 CrossRefPubMed

Moroni M, Soldatenkov V, Zhang L, Zhang Y, Stoica G, Gehan E, Rashidi B, Singh B, Ozdemirli M, Mueller SC (2004) Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res 64(20):7346–7354CrossRefPubMed

Nakashima H, Natsugoe S, Ishigami S, Okumura H, Matsumoto M, Hokita S, Aikou T (2006) Clinical significance of nuclear expression of spleen tyrosine kinase (Syk) in gastric cancer. Cancer Lett 236(1):89–94CrossRefPubMed

Ogane S, Onda T, Takano N, Yajima T, Uchiyama T, Shibahara T (2009) Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma. Int J Cancer 124(11):2651–2657. https://doi.org/10.1002/ijc.24237 CrossRefPubMed

Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB (2003) Mechanisms of Taxol resistance related to microtubules. Oncogene 22(47):7280–7295CrossRefPubMedPubMedCentral

Ou Y, Zheng X, Gao Y, Shu M, Leng T, Li Y, Yin W, Zhu W, Huang Y, Zhou Y et al (2014) Activation of cyclic AMP/PKA pathway inhibits bladder cancer cell invasion by targeting MAP4-dependent microtubule dynamics. Urol Oncol 32(1):47.e21–47.e28. https://doi.org/10.1016/j.urolonc.2013.06.017 CrossRef

Peng CL, Zhang Y, Sun QF, Zhao YP, Hao YT, Zhao XG, Cong B (2013) Inhibitory effects of syk transfection on lung cancer cell invasion. Asian Pac J Cancer Prev 14(5):3001–3003CrossRefPubMed

Poruchynsky MS, Giannakakou P, Ward Y, Bulinski JC, Telford WG, Robey RW, Fojo T (2001) Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochem Pharmacol 62(11):1469–1480CrossRefPubMed

Prinos P, Garneau D, Lucier JF, Gendron D, Couture S, Boivin M, Brosseau JP, Lapointe E, Thibault P, Durand M et al (2011) Alternative splicing of Syk regulates mitosis and cell survival. Nat Struct Mol Biol 18(6):673–679. https://doi.org/10.1038/nsmb.2040 CrossRefPubMed

Singh R, Masuda ES, Payan DG (2012) Discovery and development of spleen tyrosine kinase (Syk) inhibitors. J Med Chem 55(8):3614–3643. https://doi.org/10.1021/jm201271b CrossRefPubMed

Storr SJ, Safuan S, Woolston CM, Abdel-Fatah T, Deen S, Chan SY, Martin SG (2012) Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer. J Cell Mol Med 16(10):2422–2428. https://doi.org/10.1111/j.1582-4934.2012.01559.x CrossRefPubMedPubMedCentral

Udyavar AR, Hoeksema MD, Clark JE, Zou Y, Tang Z, Li Z, Li M, Chen H, Statnikov A, Shyr Y et al (2013) Co-expression network analysis identifies Spleen Tyrosine Kinase (Syk) as a candidate oncogenic driver in a subset of small-cell lung cancer. BMC Syst Biol 7(Suppl 5):S1. https://doi.org/10.1186/1752-0509-7-S5-S1 CrossRefPubMedPubMedCentral

Venables JP, Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Koh C, Gervais-Bird J, Lapointe E, Froehlich U, Durand M et al (2008) Identification of alternative splicing markers for breast cancer. Cancer Res 68(22):9525–9531. https://doi.org/10.1158/0008-5472.CAN-08-1769 CrossRefPubMed

Wang L, Duke L, Zhang PS, Arlinghaus RB, Symmans WF, Sahin A, Mendez R, Dai JL (2003) Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res 63(15):4724–4730PubMed

Wang L, Devarajan E, He J, Reddy SP, Dai JL (2005) Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. Cancer Res 65(22):10289–10297CrossRefPubMedPubMedCentral

Wei W, Birrer MJ (2015) Spleen tyrosine kinase confers paclitaxel resistance in ovarian cancer. Cancer Cell 28(1):7–9. https://doi.org/10.1016/j.ccell.2015.06.008 CrossRefPubMed

Yanagi S, Inatome R, Takano T, Yamamura H (2001) Syk expression and novel function in a wide variety of tissues. Biochem Biophys Res Commun 288(3):495–498CrossRefPubMed

Yu Y, Gaillard S, Phillip JM, Huang TC, Pinto SM, Tessarollo NG, Zhang Z, Pandey A, Wirtz D, Ayhan A et al (2015) Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules. Cancer Cell 28(1):82–96CrossRefPubMedPubMedCentral

Yuan Y, Wang J, Li J, Wang L, Li M, Yang Z, Zhang C, Dai JL (2006) Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin Cancer Res 12(22):6687–6695CrossRefPubMedPubMedCentral

Zhang X, Shrikhande U, Alicie BM, Zhou Q, Geahlen RL (2009) Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells. Mol Cancer Res 7(5):634–644CrossRefPubMedPubMedCentral

Zhang S, Deen S, Storr SJ, Chondrou PS, Nicholls H, Yao A, Rungsakaolert P, Martin SG (2018) Calpain system protein expression and activity in ovarian cancer. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-018-2794-2 (Epub ahead of print) CrossRefPubMedPubMedCentral

Zhou F, Hu J, Ma H, Harrison ML, Geahlen RL (2006) Nucleocytoplasmic trafficking of the Syk protein tyrosine kinase. Mol Cell Biol 26(9):3478–3491CrossRefPubMedPubMedCentral

Title: Expression of Syk and MAP4 proteins in ovarian cancer
Authors: Siwei Zhang
Suha Deen
Sarah J. Storr
Anqi Yao
Stewart G. Martin
Publication date: 01-04-2019
Publisher: Springer Berlin Heidelberg
Keywords: Ovarian Cancer
Ovarian Cancer
Cytostatic Therapy
Published in: Journal of Cancer Research and Clinical Oncology / Issue 4/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-02856-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Expression of Syk and MAP4 proteins in ovarian cancer

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2019

Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers

Retraction Note to: SOX2 oncogenes amplified and operate to activate AKT signalling in gastric cancer and predict immunotherapy responsiveness

Mistletoe in oncological treatment: a systematic review

Cancer risk in stroke survivors followed for up to 10 years in general practices in Germany

Lymph node ratio predictive of recurrence, distant metastasis, and survival in submandibular gland carcinoma patients

Computer-assisted medical image classification for early diagnosis of oral cancer employing deep learning algorithm

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page